The cheapest provider and the most transparent provider aren’t always the same one. This frames the trade-off using what we’ve verified — price versus pharmacy disclosure.
| Priority | Who leads (verified) | What you trade |
|---|---|---|
| Lowest entry price | Fifty 410 (~$133, dose-tiered) | Price rises with dose |
| Lowest flat price | Henry Meds ($179) | Pharmacy not named |
| Most pharmacy disclosure | Fifty 410 (names ProRx/BPI) | — |
| Flat + named partners + standards | NexLife (partial naming, USP <797>) | Not lowest price; specific filler per order not stated |
Fifty 410 is interesting because it leads on both lowest entry price and pharmacy disclosure — though its dose-tiered pricing climbs. If you weight transparency, the pharmacy transparency comparison is the page to read; if you weight predictable cost, see flat-rate providers. Neither is FDA-approved.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.